Read Gene

Read Gene Equity Ratio

The Equity Ratio of Read Gene (RDG.WA) as of Oct 20, 2026 is 20.40 %. In the previous year, Equity Ratio was 20.53 % — a change of -0.64% (lower).

Equity Ratio

20.40 %

YoY

-0.64%

Last updated:

Equity Ratio of Read Gene is 2025 20.40 % . Equity Ratio of Read Gene was 2024 20.53 % . It decreases by -0.64% lower compared to the previous year.

The Read Gene Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2018
20.01 PLN
Jan 1, 2019
21.43 PLN
Jan 1, 2020
20.63 PLN
Jan 1, 2021
35.20 PLN
Jan 1, 2022
35.22 PLN
Jan 1, 2023
27.52 PLN
Jan 1, 2024
20.53 PLN
Jan 1, 2025
20.40 PLN
The Read Gene Equity Ratio history
YEAREquity RatioYoY
20.40 %-0.64%
20.53 %-25.38%
27.52 %-21.86%
35.22 %+0.04%
35.20 %+70.60%
20.63 %-3.70%
21.43 %+7.06%
20.01 %+46.52%
13.66 %-17.61%
16.58 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Read Gene Stock analysis

What does Read Gene do? Read Gene SA generates revenue through medical research and testing services, focusing on malignant tumor detection, prevention, and treatment. The company offers breast cancer, colon cancer, and prostate cancer tests, along with medical consultancy, DNA tests, and supplements. Its subsidiary Dieta Antyrakowa Read-Gene Sp. z o.o. supports these services, while major shareholder GEN-PAT-MED Sp. z o.o. provides strategic backing. Clients include patients seeking cancer diagnostics and preventive care, as well as healthcare providers integrating these tests into treatment protocols. The firm's chemoprevention, clinical trials, and genetic testing specialties drive product sales to hospitals, clinics, and individual consumers. Breast cancer, colon cancer, and prostate cancer tests are key revenue streams, complemented by DNA tests and supplements. Medical consultancy services cater to institutions requiring expert guidance on cancer-related health strategies. Read Gene SA's product portfolio is structured around three core fields: chemoprevention, clinical trials, and genetic testing. The company monetizes genetic testing services, particularly for breast, colon, and prostate cancers, alongside DNA tests and supplements. Healthcare institutions and private clients form the primary customer segments, with Dieta Antyrakowa Read-Gene Sp. z o.o. serving as the operational arm for these offerings. Read Gene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Read Gene stock

Equity Ratio of Read Gene is 20.40 % in 2025.

Equity Ratio of Read Gene changed from 20.53 % to 20.40 %, representing a -0.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Read Gene since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Read Gene with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — Read Gene

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — Read Gene